【摘要】 目的 :比较米氮平与帕罗西汀治疗抑郁症的有效性和安全性。 方法 :将 64例符合CCMD -2 -R诊断标准的抑郁症患者 ,随机分为米氮平与帕罗西汀组 ,治疗 6周。用汉密顿抑郁量表 (HAMD)评定疗效 ,用副反应量表 (TESS)评定副反应。 结果 :治疗 6周后米氮平组和帕罗西汀组的有效率分别为 84%和 78% ,两组比较差异无显著性 ,但治疗 1周及 2周后 ,米氮平组的有效率高于帕罗西汀组。治疗 6周后 ,两组HAMD总分治疗前后比较 ,差异均有显著性 ,两组间比较差异无显著意义。治疗 1周及 2周后 ,米氮平组HAMD总分、焦虑躯体化和睡眠紊乱因子分的减分均较帕罗西汀组明显 ,差异有显著性。米氮平组主要不良反应是头昏、嗜睡等 ,与帕罗西汀组相比 ,差异无显著性。 结论 :米氮平是一种安全、有效的新型抗抑郁药物。起效较快 ,且有改善焦虑及睡眠作用。更多还原

【Abstract】 Objective:To compare efficacy and safety of mirtazapine and paroxetine in the treatment of major depressive disorder.Methods:Sixty-four patients who met the criteria of CCMD-2-R for depressive disorder were randomly divided into subgroups receiving treatment of mirtazapine and paroxetine respectively for six weeks. The efficacy was assessed by Hamilton depression rating scale (HAMD) and the safety was assessed by treatment emergent symptom scale (TESS). Results:After 6 weeks treatment, the effective rate of the mirtazapine group and the paroxetine group were 84% and 78%, respectively. The results have no remarkable differences in two groups. The effective rate of mirtazaoine group was higher than that of paroxetine group both after 1 week treatment and after 2 weeks treatment. After 6 weeks treatment the scores of HAMD in two groups were statistical difference before and after treatment. There was no significant difference between two groups. Both the decreased scores of HAMD and the decreased sub-scores of HAMD in anxiety somatization and sleep disturbance in mirtazaoine group were lower than that in paroxetine group after 1 week treatment and after 2 weeks treatment. There was no significant difference between two groups. The main adverse reactions of mirtazapine group were dizziness, drowsiness, etc. Adverse reactions were no obvious difference between two groups. Conclusion:Mirtazapine is a safe and effective, and rapidly responded new antidepressant. Moreover, this drug is effective in the treatment of sleep disorder and anxiety.更多还原